期刊文献+

Raloxifene与利维爱对去卵巢大鼠血脂的影响 被引量:4

The effects of Raloxifene and Livial on the serum lipid of ovariectomized rats
下载PDF
导出
摘要 目的观察Raloxifene(EVISTA)和利维爱(Livial)用于治疗去卵巢大鼠骨质疏松时对血脂的影响。方法32只4月龄雌性SD大鼠随机分为4组 :假手术组、模型组、Raloxifene组及利维爱组 ,每组8只 ,用药60天 ,采血分离血清 ,测定血清总胆固醇(TC)、甘油三脂(TG)、高密度脂蛋白(HDL_C)、低密度脂蛋白(LDL_C) ,对各组血脂测定值进行比较。结果大鼠去卵巢75天后 ,模型组血脂已有变化 ,表现为TC增高 ,HDL_C降低 ,TC、LDL_C差异无显著性 ;两药物组与模型组比较血脂改善 ,但调脂结果各不相同 :利维爱与Raloxifene均有降低TG、升高HDL_C的作用 ,前者降TC强于后者 ,对LDL_C无明显影响 ;后者升HDL_C强于前者 ,同时还有降低LDL_C作用 ;二者对TG均无明显作用 ;结论大鼠去卵巢后将发生血脂紊乱 ,Raloxifene。 Objective To study the effect of Raloxifene and Livial on the serum lipid of ovariectomized rats. Methods 32 4_month_old SD female rats were randomly divided into 4 groups, namely sham operation group, bilateral ovariectomy group(sample group), ovariectomy plus supplementary Raloxifene group(Raloxifene group), and ovariectomy plus supplementary Livial group(Livial group). Each group induded 8 rats. Experiment period was 60 days. Serum were collected to measure Cholesterol(TC)?triglyceride(TG)?high_density lipoprotein_cholesterol(HDL_C), low_density lipoprotein_cholesterol(LDL_C). Results There were significant differences between groups in serum lipid. In the sample group, TC was higher, HDL_C was lower than that in the sham operation group. In the Raloxifene group and the Livial group TC was lower than that in the sample group and in the sham operation group. In the Raloxifene group HDL_C was higher than that in the sample group and in the Livial group, HDL_C and LDL_C were lower than that in the sham operation group. There were no significant differences between groups in TG. Conclusion The ovariectomized rats had lipid metabolism disorder. Raloxifene and Livial played a role in the lipid metabolism.
出处 《中国航天工业医药》 2001年第2期26-28,共3页
关键词 RALOXIFENE 利维爱 去卵巢大鼠 血脂 绝经后 骨质疏松 药物治疗 疗效 Raloxifene Livial Ovariectomized rat Lipid
  • 相关文献

参考文献8

  • 1[1]孙瑞元编.定量药理学.第1版.北京:人民卫生出版社,1985,247.
  • 2[2]Castelo-Branco C, Vicente JJ, Figueras F. et al. Comparativeeffects of estrogens plus androgens and tibolone on bone, lipidpattern and sexuality in postmenopausal women. M aturitas2000,34(2): 161-8.
  • 3[3]Bruce Ettinger, Dennis M. Black, Bruce H. Mitlak, et al.Reduction of Vertebral Fracture Risk in PostmenopausalWomen With Osteoporosis Treated With Raloxifene. JAMA,1999.282: 637-645.
  • 4[4]Steven R. Cummings, Stephen Eckert, Kathryn A. Krueger,et al. The Effect of Raloxifene on Risk Of Breast Cancer inPostmenopausal Women. JAM A, 1999,281:2189-2197.
  • 5[5]Pierre D, Delmas. Effects of Raloxifene on Bone Mineral Den-sity, Serum Cholesterol Concentrations and Uterine Endom-etrium in Postmenopausal Women. New England Journal ofMedicine, 1997, 337:1641-1647.
  • 6[6]Eaker E, Chesebro JH, Sacks FM , et al. Cardiovascular dis-ease in women. Circulation, 1993,88:1999-2009.
  • 7[7]Stephen Hulley, MD; Deborah Grady, MD; Trudy Bush, etal. Randomized Trial of Estrogen Plus Progestin for Second-ary Prevention of Coronary Heart Disease in PostmenopausalWomen .JAM A. 1998,208:605-613.
  • 8[8]Herrington DM, Reboussin DM, Klein KP, et al. The estro-gen replacement and atherosclerosis(ERA) study: study de-sign and baseline characteristics of the cohort. Control ClinTrials, 2000, 21 (3): 257-85.

同被引文献37

  • 1崔亚利,赵德明,于书敏.利维爱(Livial)对去势雌兔动脉粥样硬化影响的病理学观察[J].中国兽医学报,2005,25(1):60-62. 被引量:3
  • 2陆媛 戴顺龄 段金虹.雌激素对动脉粥样硬化的预防性治疗作用及部分机制探讨[J].中国病理生理杂志,2000,16(10):987-987.
  • 3Fuster V. Epidemic of cardiovascular disease and stroke: the three main challenges [J]. Circulation, 1999, 99:1132 - 1137.
  • 4Herrington DM, Reboussin DM, Sharp PC. The estrogen replacement and atherosclerosis(ERα) study: Study design and baseline characteristics of the cohort [J]. Controlled Clinical Trials, 2000, 21:257- 285.
  • 5Moghadasian MH. Experimental atherosclerosis: A histotical overview[J]. Life Sciences, 2002, 70:855- 865.
  • 6Annapaula Giuliettil, Lut Overberghl, Dirk Valckx, et al. An overview of real-time quantitative PCR: Applications to quantify cytokine gene expression [J]. Methods, 2001, 25:386-401.
  • 7Winer J, Christopher Kwang SJ, Shackel I, et al. Development and validation of real-time quantitative reverse transcriptase polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro [J]. Analytical Biochemistry, 1999, 270:41 - 49.
  • 8Richards GP, Watson MA, Kingsley DH. A SYBR green, real-time RT-PCR method to detect and quantitate Norwalk virus in stools [J].Journal of Virological Methods, 2004, 116:63 - 70.
  • 9Morrison TB, Weis JJ, Wittwer CT. Quantification of low-copy transcripts by continuous SYBR green I monitoring during amplification [J]. Biotechniques, 1998, 24:954- 958,960.
  • 10Babiker FA, De Windt LJ, van Eickels M, et al. Estrogenic hormone action in the heart: regulatory network and function [J]. Cardiovascular Research, 2002, 53:709 - 719.

引证文献4

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部